CURRENCYFAIR
12.6.2019 10:32:08 CEST | Business Wire | Press release
More than a third of British expats (34 percent) are already actively seeking a formal farewell to their home country due Brexit, and a further 5 percent will seek citizenship for themselves and/or their family in case of a hard Brexit, according to a survey commissioned by international money transfer service CurrencyFair.
The survey, concluding in May, compared British expats’ preferred Brexit outcomes and plans for Brexit with the views of British citizens residing at home. Expats living in EU countries that are expected to be most significantly impacted by Brexit were surveyed, including Germany, France, the Netherlands and Ireland.
Voting with their passports
Over half of the British citizens living outside of the UK surveyed are worried about their citizenship rights as an expat (53 percent), and half (50 percent) are concerned about their citizenship rights in commonwealth countries due to Brexit, which may be a trigger for the rush to seek a citizenship berth outside of their birth country.
"Expats tend to be at the leading edge of the intersection between personal finance and current events, and their behaviour is a barometer for bigger trends and changes,” said Paul Byrne, CEO of CurrencyFair. “Our research indicates that Brexit may be forcing the hand of expats to seek citizenship they might not otherwise seek, as they search for viable options in the event of a hard Brexit and any negative economic consequences.”
Bracing for a recession
In addition to alternative citizenship, a quarter of British expats surveyed say they plan to brace for a recession in the event of a hard Brexit, and plan to liquidate UK assets (17 percent) or transfer money abroad (13 percent) if the UK crashes out of the EU without a deal. A third of expats noted that when choosing a provider to transfer money to and from the UK, transparency about fees charged ranks first as the most important aspect, tied with security and trust in service provider.
“People are hearing our message that paying marked up exchange rates and hidden fees for currency exchange isn’t sustainable for expats from a personal finance perspective,” Byrne said
Overall, expats are more worried than UK residents about the uncertainty surrounding the UK’s departure from the EU, from the amount of debt they currently have (42 percent for expats versus 20 percent for UK residents), to the impact of Brexit on their retirement (52 percent expats versus 34 percent in the UK), and their ability to buy the things they want (52 percent expats versus 41 percent in the UK).
This worry is translating into immediate action for many expats who revealed they are already focusing on paying off any unsecured debt (16 percent versus 12 percent in the UK), moving investments to lower risk funds (14 percent versus five percent in the UK), and changing retirement plans (14 percent versus two percent in the UK).
The survey revealed that UK citizens residing at home have a certain confidence when it comes to their own finances. While 54 percent are concerned that the UK economic situation will worsen over the next 12 months, the same percentage believe their individual economic situation will either stay the same or improve. Additionally, the majority of UK residents (54 percent) indicate they plan to do nothing if there is a no-deal Brexit beyond bracing for a recession (42 percent).
“The survey suggests that expats and UK citizens residing at home have contrasting views when it comes to how they anticipate Brexit will affect their lives. It’s clear that when it comes to Brexit, where one stands on the issues depends on where one sits in the world,” said Byrne.
The Irish question
In the Brexit blame game, the Irish government gets off scot-free. Only four percent of British expats surveyed hold the Irish government responsible, despite assertions in some media quarters that the Irish government has ‘overplayed its hand’ on Brexit. A full twenty-seven percent of British expats in Ireland, however, blame the mainstream media or ‘fake news’ for the state of Brexit negotiations. Interestingly, British expats living in Ireland are significantly more likely than others to blame the British public for the current state of affairs. Twenty-seven percent say the British public is at fault, compared to just 16 percent of expats in other countries that blame their fellow countrymen.
Leadership vacuum
The likes of British prime ministers Theresa May and David Cameron, however, take the lion’s share of blame for the current state of Brexit negotiations. Both UK citizens residing at home and expats struggled to suggest an appropriate alternative, with only one in 10 expats choosing Michael Gove, and one in 10 UK citizens residing at home choosing Boris Johnson. When asked which notable person - living or dead - would have Brexit sorted by now if they were in charge, 32 percent of UK nationals said former prime minister Margaret Thatcher and 24 percent said they felt former prime minister Winston Churchill would get the job done. Expats living in France and Germany felt leaders in their adoptive countries, president Emmanuel Macron and chancellor Angela Merkel, respectively, would do a better job handling Brexit. Kylie Minogue ranked second in both Germany and The Netherlands with 15 percent and 18 percent respectively choosing the singer. Twelve percent of expats surveyed in the Netherlands chose Meghan, Duchess of Sussex, formerly known as Meghan Markle.
All figures, unless otherwise stated, are from YouGov Plc. Total sample size was 664 adults. Fieldwork was undertaken between 18th April - 2nd May 2019. The survey was carried out online. The figures have been weighted and are representative of all GB adults (aged 18+).
-30-
CurrencyFair is an international money transfer platform focused on providing the best available exchange rates and experience for customers who need to send money and make payments overseas. CurrencyFair’s 150,000 strong user-community have traded more than €8 billion and saved more than €205 million using the service. Our unique peer-to-peer model and secure, state-of-the-art technology, raises the industry standard in designing technology-led foreign currency services for web, IOS and Android use. The company has offices in Ireland, Singapore, Hong Kong and Australia, and announced plans to expand further across Asia in 2019 after acquiring Convoy Payments (Hong Kong) in December 2018.
…
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005288/en/
Contact:
Killeen Kelly killeenkelly@currencyfair.com +353 87 380 6879
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
